World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
18932
World Ranking
19174
National Ranking
1730

Overview

Eliot H. Ohlstein is affiliated with GlaxoSmithKline in the United Kingdom and has contributed extensively to the field of medicine, with a particular focus on cardiology, cardiovascular medicine, surgery, pharmacology, pulmonary and respiratory medicine, and molecular biology. Their research spans a variety of topics related to cardiovascular health, pulmonary diseases, and molecular mechanisms involved in tissue remodeling and fibrosis.

The scientist has published work in several notable venues, including:

  • IUPHAR/BPS Guide to Pharmacology CITE
  • British Journal of Pharmacology
  • Pharmacological Reviews

Key areas of study for Eliot H. Ohlstein include:

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pharmacology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology

Their research covers main topics such as:

  • Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Apelin-related biomedical research
  • Cardiovascular Disease and Adiposity
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Cardiac Fibrosis and Remodeling
  • Tissue Engineering and Regenerative Medicine
  • S100 Proteins and Annexins

Frequently collaborating with other researchers, Eliot H. Ohlstein has worked extensively alongside Anthony P. Davenport, Stephen A. Douglas, Alain Fournier, Adel Giaid, and Henry Krum. These collaborations have yielded multiple publications and contributed to a wider understanding of pharmacology and cardiovascular diseases.

Recent significant publications include:

  • International Union of Basic and Clinical Pharmacology. CXVI: NC-IUPHAR and Pharmacological Reviews: 30+ Years of Collaboration-Editorial, 2024, Pharmacological Reviews
  • Therapeutic targets of fibrosis: Translational advances and current challenges, 2023, British Journal of Pharmacology
  • Endothelin receptors in GtoPdb v.2023.1, 2023, IUPHAR/BPS Guide to Pharmacology CITE
  • Urotensin receptor in GtoPdb v.2023.1, 2023, IUPHAR/BPS Guide to Pharmacology CITE
  • Urotensin receptor in GtoPdb v.2021.3, 2021, IUPHAR/BPS Guide to Pharmacology CITE

Best Publications

  • Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

    Robert S. Ames;Henry M. Sarau;Johathan K. Chambers;Robert N. Willette

  • Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats: Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size

    Anne M. Romanic;Raymond F. White;Anthony J. Arleth;Eliot H. Ohlstein

  • Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators

    BT Mellion;LJ Ignarro;EH Ohlstein;EG Pontecorvo

  • Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation

    Feng Gao;Erhe Gao;Tian-Li Yue;Eliot H. Ohlstein

  • Chemokine Receptors in Human Endothelial Cells: FUNCTIONAL EXPRESSION OF CXCR4 AND ITS TRANSCRIPTIONAL REGULATION BY INFLAMMATORY CYTOKINES *

    Shalley K. Gupta;Paul G. Lysko;Kodandaram Pillarisetti;Eliot Ohlstein

  • In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

    Tian-li Yue;Jun Chen;Weike Bao;Padma K. Narayanan

  • Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia.

    Frank C. Barone;Robert K. Clark;William J. Price;Raymond F. White

  • Congestive heart failure and expression of myocardial urotensin II

    Stephen A Douglas;Lara Tayara;Eliot H Ohlstein;Nadine Halawa

  • Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.

    F.C. Barone;E.A. Irving;A.M. Ray;J.C. Lee

  • Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

    Stephen A Douglas;Anthony C Sulpizio;Valerie Piercy;Henry M Sarau

  • SB 239063, a Second-Generation p38 Mitogen-Activated Protein Kinase Inhibitor, Reduces Brain Injury and Neurological Deficits in Cerebral Focal Ischemia

    F C Barone;E A Irving;A M Ray;J C Lee

  • Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

    Stephen A. Douglas;Eliot H. Ohlstein

  • IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels

    Anthony J. Harmar;Rebecca A. Hills;Edward M. Rosser;Martin Jones

  • Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.

    M R MacLean;D Alexander;A Stirrat;M Gallagher

  • Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

    Alison Stirrat;Marie Gallagher;Stephen A. Douglas;Eliot H. Ohlstein

  • Endothelin levels increase in rat focal and global ischemia

    F. C. Barone;M. Y.-T. Globus;W. J. Price;R. F. White

  • Activation of Peroxisome Proliferator-Activated Receptor-α Protects the Heart From Ischemia/Reperfusion Injury

    Tian-li Yue;Weike Bao;Beat M. Jucker;Juan-li Gu

  • EXTRACELLULAR SIGNAL-REGULATED KINASE PLAYS AN ESSENTIAL ROLE IN HYPERTROPHIC AGONISTS, ENDOTHELIN-1 AND PHENYLEPHRINE-INDUCED CARDIOMYOCYTE HYPERTROPHY

    Tian-Li Yue;Juan-Li Gu;Chuanlin Wang;Alastair D. Reith

  • Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.

    B T Mellion;L J Ignarro;C B Myers;E H Ohlstein

  • SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist

    E H Ohlstein;P Nambi;S A Douglas;R M Edwards

Frequent Co-Authors

Giora Z. Feuerstein
Giora Z. Feuerstein Debina Diagnostics
Ponnal Nambi
Ponnal Nambi Pfizer (United States)
Anthony P. Davenport
Anthony P. Davenport University of Cambridge
Louis J. Ignarro
Louis J. Ignarro University of California, Los Angeles
Henry M. Sarau
Henry M. Sarau GlaxoSmithKline (United Kingdom)
John C. Lee
John C. Lee The University of Texas Health Science Center at San Antonio
Raymond Baker
Raymond Baker MSD (United States)
Richard R. Neubig
Richard R. Neubig Michigan State University
William A. Catterall
William A. Catterall University of Washington
Anthony J. Harmar
Anthony J. Harmar University of Edinburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is just one of many pathways in the healthcare field. If you’re exploring alternatives, several online degrees offer promising careers with flexible entry points. For those interested in direct patient care but seeking a faster or less test-intensive route, there are nursing schools that don't require teas or hesi, making it easier to start your nursing journey.

If you are drawn toward the organizational or management side of healthcare, pursuing a healthcare administration degree online can open doors to roles in hospital administration, healthcare policy, or operations. Nurses looking to advance their careers might consider rn to fnp bridge programs, which provide a path to becoming a Family Nurse Practitioner without starting over.

Nutrition is another crucial aspect of healthcare, and earning an online bs in nutrition equips you for careers in dietetics, wellness coaching, or public health. Each pathway meets different interests and lifestyle needs, giving you many options to impact the health sector beyond medical school.

Best Scientists Citing Eliot H. Ohlstein

Trending Scientists

Recently Published Articles